Villalta Score for Post-Thrombotic Syndrome (PTS)

Why use it

PTS is the most common long-term complication of DVT and is associated with substantial impairment in quality of life, comparable to other major chronic diseases. Without a validated diagnostic framework, PTS is often underdiagnosed or misdiagnosed as recurrent DVT. The Villalta scale provides: (1) a standardized positive diagnosis of PTS distinct from the underlying thrombotic condition; (2) objective severity grading to guide treatment escalation (compression stockings for mild/moderate vs. pharmacological/interventional therapy for severe); (3) a validated outcome measure for clinical trials of PTS prevention (thrombolysis, thrombectomy, compression) and treatment; (4) identification of patients who may benefit from interventions such as venous angioplasty/stenting for residual iliac vein obstruction.

About

The Villalta scale is the internationally validated standard for diagnosing and grading the severity of post-thrombotic syndrome (PTS), a chronic complication of deep vein thrombosis (DVT) affecting 20–50% of patients within 2 years of the index thrombotic event. The scale was originally introduced at a meeting of the Italian Society of Haematology in 1994 (Villalta et al., Haemostasis 1994, abstract) and subsequently published and validated by Prandoni and colleagues in multiple prospective cohort studies. The Villalta scale is endorsed by the International Society on Thrombosis and Haemostasis (ISTH) and is the recommended outcome measure for PTS in clinical trials and practice. The scale assesses 11 items: five patient-reported symptoms (pain, cramps, heaviness, paresthesia, pruritus) and six clinician-assessed signs (pretibial edema, skin induration, hyperpigmentation, pain during calf compression, venous ectasia, redness). Each item is rated on a 4-point ordinal scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The presence of a venous ulcer — regardless of the numerical score — automatically classifies the patient as having severe PTS. Total scores (without ulcer) range from 0 to 33. Validated severity thresholds: score ≤4 = no PTS; 5–9 = mild PTS; 10–14 = moderate PTS; ≥15 or venous ulcer = severe PTS. PTS arises from valve destruction and venous obstruction caused by thrombosis and post-thrombotic remodeling, leading to sustained ambulatory venous hypertension, venous reflux, and impaired calf muscle pump function. Risk factors for PTS development include proximal DVT (iliofemoral > femoropopliteal), ipsilateral DVT recurrence, obesity, varicose veins, inadequate anticoagulation, and the absence of elastic compression therapy. The Villalta scale has high inter-rater reliability (ICC 0.78–0.96) and is sensitive to change over time, making it suitable for monitoring treatment response.

When to use

• Assessment for PTS in all patients at 3–6 months after a first DVT episode and at regular intervals thereafter
• Diagnosis of PTS — score ≥5 at any assessment ≥3 months after the index DVT confirms PTS (ISTH 2009 definition)
• Severity grading to guide treatment decisions (compression, venoactive drugs, interventional therapy)
• Serial monitoring of PTS severity during follow-up (annually or more frequently in severe cases)
• Outcome measurement in clinical trials evaluating DVT treatment strategies (catheter-directed thrombolysis, mechanical thrombectomy, IVC filter) for PTS prevention
• Assessment of patients with suspected PTS presenting with chronic leg pain, swelling, or skin changes after previous DVT
• NOT applicable within the first 3 months of DVT — acute DVT symptoms overlap with PTS features; assess only after 3 months of adequate anticoagulation
• NOT for primary diagnosis of DVT — duplex ultrasound is required to confirm new thrombosis

Formula

Pearls & pitfalls

• The ISTH 2009 consensus statement defines PTS as a Villalta score ≥5 on two separate assessments at least 3 months apart after the index DVT, or the presence of a venous ulcer. A score ≥5 at a single assessment is clinically diagnostic in practice.
• A venous ulcer automatically classifies the patient as severe PTS regardless of the numerical score — do not add the ulcer as points but flag it separately.
• The Villalta scale should be applied to the affected (thrombosed) limb. If bilateral DVT, assess both legs separately.
• Timing matters: the Villalta score in the first 1–3 months after DVT may reflect acute thrombotic inflammation rather than established PTS. The scale is most reliably interpretable ≥3 months after the acute event.
• Proximal (iliofemoral) DVT carries 2–3× higher risk of developing moderate-to-severe PTS than distal (calf) DVT. Patients with iliofemoral DVT who are symptomatic despite anticoagulation should be assessed for early catheter-directed thrombolysis (CDT) or pharmacomechanical thrombectomy — the ATTRACT trial (2017) showed CDT reduced PTS severity (Villalta score) but not incidence at 24 months.
• Graduated elastic compression stockings (below-knee, Class II, 30–40 mmHg) were recommended for PTS prevention for decades based on the Brandjes 1997 trial. However, the SOX trial (Kahn et al. 2014, Lancet) — the largest placebo-controlled RCT — found NO reduction in PTS incidence with routine compression stockings after DVT. Current guidelines no longer mandate routine stocking use for DVT secondary PTS prevention in all patients, though they remain first-line treatment for established PTS.
• Rivaroxaban and other DOACs appear to have similar PTS rates compared to vitamin K antagonists — the choice of anticoagulant does not substantially alter PTS risk after the first DVT based on available data.
• Ipsilateral DVT recurrence is the single strongest modifiable risk factor for PTS development — optimal anticoagulation duration and adherence are critical for PTS prevention.
• The Ginsberg score (presence/absence of PTS) and the CEAP clinical classification (C0–C6) are alternative but less validated or less specific measures for PTS. The Villalta scale is superior for PTS-specific severity assessment.
• Inter-rater reliability is highest when clinicians are trained together. When comparing serial Villalta scores over time, the same assessor should ideally perform the examination, or use standardized photographic and palpation techniques.

Next steps

No PTS (score ≤4): Reassure the patient. Continue anticoagulation per guidelines. Encourage ambulation and graduated compression stockings (Class II, 30–40 mmHg) for DVT secondary prevention if tolerated. Reassess annually or if symptoms develop. Mild PTS (score 5–9): Graduated compression stockings (Class II, 23–32 mmHg or 30–40 mmHg) are the cornerstone of treatment. Patient education on elevation, exercise, and weight management. Venoactive drugs (diosmin/hesperidin 500 mg twice daily, horse chestnut extract) may provide symptomatic benefit. Reassess at 3–6 months. Moderate PTS (score 10–14): Optimize compression therapy with higher-class stockings or multi-layer bandaging. Consider pneumatic compression device for home use. Venoactive drugs. Duplex imaging to assess for residual obstruction and reflux — iliac vein obstruction may benefit from endovenous intervention. Severe PTS (score ≥15 or venous ulcer): Specialist vascular/venous medicine referral. Wound care for venous ulcers (multi-layer compression bandaging is standard of care). Assessment for iliac/femoral vein obstruction — endovascular recanalization (PTA/stenting) of occluded iliac veins may dramatically reduce symptoms. Inelastic (Unna boot) or elastic multilayer bandaging until ulcer healing, followed by Class II–III stockings for maintenance.

Evidence

Villalta S et al. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. Haemostasis. 1994;24(Suppl 1):158a. Original development abstract. Prandoni P et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1-7. PMID:8644983 — prospective validation of PTS assessment. Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C; Subcommittee on Control of Anticoagulation. Definition of post-thrombotic syndrome of the leg for use in clinical investigations. J Thromb Haemost. 2009;7(5):879-883. PMID:19175497. ISTH 2009 definition using Villalta score ≥5. Vedantham S et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis (ATTRACT trial). N Engl J Med. 2017;377(23):2240-2252. PMID:29211671.

References

1. Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C. Definition of post-thrombotic syndrome of the leg for use in clinical investigations. J Thromb Haemost. 2009;7(5):879-883. — link
2. Prandoni P, Lensing AWA, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1-7. — link
3. Vedantham S et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis (ATTRACT trial). N Engl J Med. 2017;377(23):2240-2252. — link
4. Kahn SR, Shrier I, Julian JA et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008;149(10):698-707. — link
5. Kahn SR et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial (SOX trial). Lancet. 2014;383(9920):880-888. — link